Oxford, 20 November 2018 – OMass Therapeutics (“OMass”), a biotechnology company using structural mass spectrometry to discover novel medicines is expanding and building out its expert team. We value collaboration, continuous learning, free-thinking and innovation at all levels of our company. Our modern headquarters are located in Oxford, an area famous for scientific research and discovery.

Our current vacancies include:
• Protein biochemists for purification and expression of membrane-bound and soluble proteins
• Mass spectrometrists with experience of native MS
• Computational chemists
• Bioinformaticians

OMass is developing novel medicines using its suite of proprietary technologies based on high-resolution mass spectrometry of intact protein assemblies. The technology enables detection of drug leads that not only bind to the target complex, but also exert a functional effect through modulation of complex formation. These platforms are being applied to drug discovery for a variety of complex targets, including membrane receptors, addressing severe unmet medical needs.

To find out more please visit the careers section of our website at www.omass.com/careers.

–

Further information:

JW Communications +44 (0)7818430877
Julia Wilson juliawilsonuk@gmail.com

Notes for Editors:

About OMass Therapeutics

OMass Therapeutics is a private biotechnology company, focused on structural mass spectrometry to discover novel medicines. The company uses its suite of proprietary technologies based on high-resolution mass spectrometry to study intact protein assemblies. The technology enables detection of drug leads that not only bind to the target complex, but also exert a functional effect through modulating complex formation. These methods are being applied to drug discovery for a variety of complex targets, including membrane receptors, addressing severe unmet medical needs. OMass is backed by Syncona Ltd and Oxford Sciences Innovation. For further information please visit the Company’s website at: www.omass.com.